Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 7/20 | 0.34 |
| ▸ | RAB9A | P51151 | 6/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16414760 | 0.85 | TAAR1 (0.45) | TAAR1LMNAMAPK1KMT2ANPC1 | |
| SCHEMBL18669295 | 0.84 | TAAR1 (0.44) | TAAR1LMNAMAPK1KMT2ANPC1 | |
| SCHEMBL16528692 | 0.84 | TAAR1 (0.44) | TAAR1LMNAMAPK1KMT2ANPC1 | |
| SCHEMBL4433970 | 0.83 | TAAR1 (0.46) | TAAR1LMNAMAPK1KMT2ANPC1 | |
| SCHEMBL27821847 | 0.80 | TAAR1 (0.42) | TAAR1LMNAMAPK1NPC1RAB9A | |
| SCHEMBL7291396 | 0.80 | TAAR1 (0.40) | TAAR1LMNAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4433472 | 0.80 | TAAR1 (0.46) | TAAR1LMNAMAPK1KMT2ANPC1 | |
| SCHEMBL4433475 | 0.80 | TAAR1 (0.46) | TAAR1LMNAMAPK1KMT2ANPC1 | |
| SCHEMBL16993195 | 0.80 | MEN1 (0.50) | TAAR1KMT2AALDH1A1 | |
| SCHEMBL31691616 | 0.77 | TAAR1 (0.41) | TAAR1LMNAMAPK1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3298011-B1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | disclosed |
| EP-3298011-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016191172-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2016-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | TAAR1 4866/4885LMNA 3513/4885MAPK1 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.